Fulcrum Therapeutics (FULC) EBITDA (2020 - 2025)
Historic EBITDA for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to -$19.4 million.
- Fulcrum Therapeutics' EBITDA rose 723.12% to -$19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$77.0 million, marking a year-over-year decrease of 19301.5%. This contributed to the annual value of -$9.5 million for FY2024, which is 9021.56% up from last year.
- Per Fulcrum Therapeutics' latest filing, its EBITDA stood at -$19.4 million for Q3 2025, which was up 723.12% from -$19.8 million recorded in Q2 2025.
- Fulcrum Therapeutics' 5-year EBITDA high stood at $52.5 million for Q2 2024, and its period low was -$34.0 million during Q2 2022.
- In the last 5 years, Fulcrum Therapeutics' EBITDA had a median value of -$24.1 million in 2021 and averaged -$20.0 million.
- Its EBITDA has fluctuated over the past 5 years, first surged by 29233.48% in 2024, then tumbled by 13774.86% in 2025.
- Quarter analysis of 5 years shows Fulcrum Therapeutics' EBITDA stood at -$23.8 million in 2021, then dropped by 17.56% to -$28.0 million in 2022, then decreased by 0.07% to -$28.0 million in 2023, then skyrocketed by 39.92% to -$16.8 million in 2024, then decreased by 15.57% to -$19.4 million in 2025.
- Its last three reported values are -$19.4 million in Q3 2025, -$19.8 million for Q2 2025, and -$16.8 million during Q4 2024.